All In Biotech

Drug Trial Radar · NCT05553808

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1

A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants

Last checked: Nov 19, 2026Latest source record: Jan 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

105

Actual

Start

Jan 24, 2019

Primary completion

Sep 23, 2021

Study completion Sep 23, 2021

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
iTeos Belgium SA
First posted
Sep 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study has assessed the clinical activity of novel regimen (Feladilimab plus Docetaxel) with SOC (Docetaxel) in participants with NSCLC.

Conditions

  • Neoplasms

Interventions

  • DocetaxelDrug

    Docetaxel was administered as IV infusion.

  • FeladilimabDrug

    Feladilimab was administered as IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: Up to 2 years

Locations

43 sites in 12 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Nashville, Tennessee

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Bordeaux, France

  • GSK Investigational Site

    Caen, France

  • GSK Investigational Site

    Nantes, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Villejuif, France

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Gauting, Bavaria, Germany

  • GSK Investigational Site

    Immenhausen, Hesse, Germany

  • GSK Investigational Site

    Leipzig, Saxony, Germany

  • GSK Investigational Site

    Großhansdorf, Schleswig-Holstein, Germany

  • GSK Investigational Site

    Meldola (FC), Emilia-Romagna, Italy

  • GSK Investigational Site

    Ravenna, Emilia-Romagna, Italy

  • GSK Investigational Site

    Milan, Lombardy, Italy

  • GSK Investigational Site

    Orbassano (TO), Piedmont, Italy

  • GSK Investigational Site

    Maastricht, Netherlands

  • GSK Investigational Site

    Lodz, Poland

  • GSK Investigational Site

    Poznan, Poland

  • GSK Investigational Site

    Warsaw, Poland

  • GSK Investigational Site

    Bucharest, Romania

  • GSK Investigational Site

    Craiova, Romania

  • GSK Investigational Site

    Floreşti, Romania

  • GSK Investigational Site

    Otopeni, Romania

  • GSK Investigational Site

    Timișoara, Romania

  • GSK Investigational Site

    Chelyabinsk, Russia

  • GSK Investigational Site

    Saint Petersburg, Russia

  • GSK Investigational Site

    Saint Petersburg, Russia

  • GSK Investigational Site

    Cheongju-si, South Korea

  • GSK Investigational Site

    Gyeonggi-do, South Korea

  • GSK Investigational Site

    Seongnam, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.